SCHEMBL2959148

SCHEMBL2959148

O=C(O)CNC(=O)c1cc2[nH]ccc2cn1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 11/20 0.47
KDM4C Q9H3R0 1/20 0.43
HDAC6 Q9UBN7 2/20 0.41
EGFR P00533 1/20 0.41
AKR1B1 P15121 1/20 0.41
HDAC3 O15379 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC10 Q969S8 1/20 0.40
HDAC11 Q96DB2 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC9 Q9UKV0 1/20 0.40
HDAC5 Q9UQL6 1/20 0.40
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
ENPP2 Q13822 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1218256 0.89 HDAC6 (0.50) EGLN1KDM4CHDAC6EGFRAKR1B1
SCHEMBL2231485 0.79 KDM4E (0.51) EGLN1KDM4CHDAC6KDM4EALDH1A1
SCHEMBL1208104 0.77 EGLN1 (0.62) EGLN1KDM4CEGFRHDAC3HDAC1
SCHEMBL1609275 0.76 EGFR (0.41) EGLN1HDAC6EGFR
SCHEMBL14226872 0.74 ENPP2 (0.42) HDAC6KDM4EALDH1A1HPGDENPP2
SCHEMBL1207829 0.74 LCK (0.44) HDAC6KDM4EALDH1A1HPGDENPP2
SCHEMBL29965053 0.74 GABRA1 (0.49) KDM4EALDH1A1HPGDHSD17B10
SCHEMBL27577568 0.74 GABRA1 (0.49) KDM4EALDH1A1HPGDHSD17B10
SCHEMBL1222503 0.72 HDAC1 (0.57) HDAC6HDAC3HDAC4HDAC1HDAC7
SCHEMBL1219368 0.72 CHRNA7 (0.48) EGLN1KDM4CEGFRAKR1B1EGLN3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2227232-A1 METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION Fibrogen, Inc. (US) 2010-09-15 EP disclosed
US-20100144737-A1 METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION FIBROGEN, INC. (US) 2010-06-10 US disclosed
WO-2009075822-A1 METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION FIBROGEN, INC. (US) 2009-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144737-A1 METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION NFATC1, CD4, IL2 EGLN1 238/4885KDM4C 1494/4885HDAC6 605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.